Table 2. Antibiotic susceptibility pattern of E. coli in male and female patients.
Antibiotic |
Pattern |
Gender |
Total |
P Value |
|
Male % (n) |
Female %(n) |
||||
Amoxycillin (20 μg) |
S |
13.7 (21) |
9.0 (27) |
10.6 (48) |
0.085 |
R |
86.3(132) |
91.0 (273) |
89.4 (405) |
||
Cephradine (30 μg) |
S |
35.3(54) |
24.0 (72) |
27.8 (126) |
0.014*
|
I |
3.9(6) |
2.0 (6) |
2.6 (12) |
||
R |
60.8 (93) |
74.0 (222) |
69.5 (315) |
||
Ceftriaxone (30 μg) |
S |
43.1 (66) |
108(36.0) |
38.4 (174) |
0.186
|
I |
0.0(0) |
1.0 (3) |
.7 (3) |
||
R |
56.9 (87) |
63.0 (189) |
60.9 (276) |
||
Ceftazidime (30 μg)
|
S |
52.9 (81) |
44.0 (132) |
47.0 (213) |
0.093 |
I |
7.8 (12) |
6.0 (18) |
6.6 (30) |
||
R |
39.2 (60) |
50.0 (150) |
46.4 (210) |
||
Imipenem (10 μg) |
S |
90.2 (138) |
92.0 (276) |
91.4 (414 () |
0.002*
|
I |
3.9 (6) |
0.0(0) |
1.3 (6) |
||
R |
5.9 (9) |
8.0 (24) |
7.3 (33) |
||
Erythromycin (15 μg) |
S |
3.9 (6) |
1.0 (3) |
2.0 (9) |
0.04*
|
R |
96.1 (147) |
99.0 (297) |
98.0 (444) |
||
Co_trimoxazole (25μg) |
S |
19.6 (30) |
22.0 (66) |
21.2 (96) |
0.546
|
I |
0.0(0) |
1.0 (3) |
.7 (3) |
||
R |
80.4 (123) |
77.0 (231) |
78.1 (354) |
||
Moxifloxacin (5 μg) |
S |
37.3 (57) |
32.0 (96) |
33.8 (153) |
0.361 |
I |
11.8 (18) |
10.0 (30) |
10.6 (48) |
||
R |
51.0 (78) |
58.0 (174) |
55.6 (252) |
||
Gentamicin (10 μg) |
S |
68.6 (105) |
55.0 (165) |
59.6 (270) |
0.004* |
I |
5.9 (9) |
15.0 (45) |
11.9 (54) |
||
R |
25.5 (39) |
30.0 (90) |
28.5 (129) |
||
Netilmycin (30 μg) |
S |
72.5 (111) |
70.0 (210) |
321(70.9) |
0.328 |
I |
5.9 (9) |
10.0 (30) |
8.6 (3939) |
||
R |
21.6 (33) |
20.0 (60) |
20.5 (93) |
||
Nalidixic_Acid (30 μg) |
S |
29.4 (45) |
15.0 (45) |
19.9 (90) |
0.001*
|
I |
0.0(0) |
1.0 (3) |
0.7 (3) |
||
R |
70.6 (108) |
84.0 (252) |
79.5 (360) |
||
Ciprofloxacin (5 μg) |
S |
39.2 (60) |
34.0 (102) |
35.8 (162) |
0.022* |
I |
7.8 (12) |
3.0 (9) |
4.6 (21) |
||
R |
52.9 (81) |
63.0 (189) |
59.6 (270) |
||
Levofloxacin (5 μg) |
S |
43.1 (66) |
36.0 (108) |
38.4 (174) |
0.004* |
I |
11.8 (18) |
5.0 (15) |
7.3 (33) |
||
R |
45.1 (69) |
59.0 (177) |
54.3 (246) |
||
Nitrofurantoin (300 μg) |
S |
78.4 (120) |
85.0 (255) |
82.8 (375) |
0.013*
|
I |
0.0(0) |
2.0 (6) |
1.3 (6) |
||
R |
21.6 (33) |
13.0 (39) |
15.9 (72) |
||
Amikacin (30 μg) |
S |
76.5 (117) |
72.0 (216) |
73.5 (333) |
0.432 |
I |
5.9(9) |
9.0 (27) |
7.9 (36) |
||
R |
17.6 (27) |
19.0 (57) |
18.5 (84) |
||
Aztreonam (30 μg) |
S |
31.4 (48) |
32.0 (96) |
31.8 (144) |
0.012* |
I |
15.7 (24) |
7.0 (21) |
9.9 (45) |
||
R |
52.9 (81) |
61.0 (183) |
58.3 (264) |
||
(n)- indicates the number of patients, *Using Fisher Exact test because expected frequency < 0.05. S=Sensitive, I=Intermediate, R=Resistant
|